Schizophrenia: all 3,539 studies

Page 31 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• Social Cognition and Interaction Training for Improving Social Functioning in People With SchizophreniaCompletedNCT00601224Phase 1
• Quality of Life in Schizophrenic PatientsCompletedNCT00597168
• Omega-3 Fatty Acid Deficiency Replacement in Early SchizophreniaCompletedNCT00585390Phase 2/3
• Antipsychotics and Blood Vessel FunctionCompletedNCT00585273
• Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and OverweightCompletedNCT00584519
• Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to ClozapineCompletedNCT00581932
• Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia PatientsTerminatedNCT00581243Phase 1
• Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of SchizophreniaCompletedNCT00580125Phase 2
• Study of the Effects of Glycine on Symptoms and Memory in Patients With SchizophreniaTerminatedNCT00575848Phase 1
• A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With SchizophreniaCompletedNCT00573417Phase 4
• Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) StudyCompletedNCT00573300
• The Psychiatric Rehabilitation Approach to Weight LossCompletedNCT00572247Not applicable
• Effect on Metabolic Parameters of Abilify in SPRStatus unknownNCT00569764
• Prevalence of the Metabolic Syndrome in SPR Taking AntipsychoticsStatus unknownNCT00569504
• A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II StudyCompletedNCT00567710Phase 2
• Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original StudyCompletedNCT00567281Not applicable
• A Study Of Adjunctive Treatment Of Cognitive Deficits In SchizophreniaCompletedNCT00567203Phase 1
• Remediation of Schizophrenia Sensory Gating Deficit With AripiprazoleStatus unknownNCT00567099Not applicable
• Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-EffectsCompletedNCT00567034Phase 1
• Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant SchizophreniaCompletedNCT00565175Phase 4
• Transcranial Magnetic Stimulation (TMS) in SchizophreniaStatus unknownNCT00564096Phase 2/3
• Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than RisperidoneStatus unknownNCT00563017Not applicable
• Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong ChineseCompletedNCT00562926
• Sensorimotor Gating in SchizophreniaCompletedNCT00561561Not applicable
• Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)Status unknownNCT00560677
• Effects of Motivating People With Schizophrenia to ExerciseCompletedNCT00559572Not applicable
• A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.CompletedNCT00558298Phase 3
• Quetiapine Induced Neuroplasticity in First-episode Schizophrenic PatientsCompletedNCT00554658Phase 4
• Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in SchizophreniaCompletedNCT00552500Not applicable
• Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With SchizophreniaCompletedNCT00546403Not applicable
• Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic AgentsCompletedNCT00545467Phase 4
• Effectiveness of Anti-Psychotic in GPs SettingCompletedNCT00543088
• Study Comparing Bioavailability of Oral Formulations of VabicaserinCompletedNCT00541996Phase 1
• Antipsychotic Polypharmacy: Prevalence, Background and ConsequencesCompletedNCT00541398Not applicable
• Bone Density in Patients With SchizophreniaCompletedNCT00540267
• Changes in Heart Rhythms Associated With Antipsychotic Drug TreatmentCompletedNCT00538122
• A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With SchizophreniaCompletedNCT00538070Not applicable
• Schizophrenia Sensory Gating Deficit With QuetiapineCompletedNCT00536783
• Bexarotene Augmentation of Antipsychotic Treatment for Chronic SchizophreniaCompletedNCT00535574Phase 3
• Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia PatientsWithdrawnNCT00534898Phase 3
• Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine EffectCompletedNCT00534222
• Metabolic Profile and Anthropometric Changes in SchizophreniaCompletedNCT00534183Not applicable
• A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)CompletedNCT00533260
• Proof of Concept Study of Cognitive Improvement in Patients With SchizophreniaCompletedNCT00528905Phase 2
• β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugSCompletedNCT00528359
• First Time in Human Study With GSK1018921CompletedNCT00527020Phase 1
• An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care TreatmentCompletedNCT00526877Phase 4
• Oxygen Therapy in SchizophreniaStatus unknownNCT00525863Phase 3
• A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical ConditionCompletedNCT00525304Not applicable
• Digital Voice Analysis in Patients With SchizophreniaCompletedNCT00524979
• Seroquel Long-Term NIS for Schizophrenia PatientsCompletedNCT00523783
• The Effects of Varenicline on Cognitive Function in Patients With SchizophreniaCompletedNCT00523445Phase 3
• Recovery Group PilotCompletedNCT00522613Not applicable
• A Study for Participants With SchizophreniaCompletedNCT00520923Phase 2
• Efficacy of an Occupational Time Use Intervention for People With Serious Mental IllnessCompletedNCT00520728Phase 1
• Health Evaluation of Abilify Long-term TherapyCompletedNCT00520650Phase 4
• Emotional and Cognitive Abilites of Schizophrenia Patients at Various Time PointsStatus unknownNCT00518999
• Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic PatientsTerminatedNCT00515489
• How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance ProgramsCompletedNCT00514423Not applicable
• Study on the Safety of Risperidone on Obese or Overweight Patients With SchizophreniaTerminatedNCT00511628
• Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot StudyCompletedNCT00511277Phase 4
• An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.CompletedNCT00510211
• Complex Problem Solving Training in Schizophrenic PatientsCompletedNCT00507988Not applicable
• Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male SubjectsCompletedNCT00505973Phase 1
• Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective DisorderCompletedNCT00501618Phase 4
• Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia PatientsCompletedNCT00501163
• Enhancing Motivation To Quit Smoking In Smokers With Serious Mental IllnessCompletedNCT00500695Phase 1
• A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.CompletedNCT00500201Phase 1
• A Comparison of Two Cognitive Batteries in People With SchizophreniaCompletedNCT00499044Not applicable
• Quality of Life (QOL) in Female Patient With SchizophreniaTerminatedNCT00498004Phase 4
• The Compliance Project Concerning People With SchizophreniaCompletedNCT00497848Not applicable
• The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in SchizophreniaCompletedNCT00495352Phase 4
• A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.CompletedNCT00495118Phase 3
• Antipsychotic Polypharmacy in SchizophreniaCompletedNCT00493233Not applicable
• Sarcosine or D-Serine Add-on Treatment for Chronic SchizophreniaCompletedNCT00491569Phase 2
• ACP-104 in Acutely Psychotic Subjects With SchizophreniaCompletedNCT00490516Phase 2
• The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With SchizophreniaTerminatedNCT00488891
• Pilot Study of Atomoxetine To Enhance COgnition In Patients With SchizophreniaCompletedNCT00488163Phase 4
• FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute PsychosisTerminatedNCT00486798Phase 3
• Weight Gain Management in Patients With SchizophreniaCompletedNCT00486005Phase 4
• Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaCompletedNCT00485901Phase 3
• Assessment of a Weight Management Program for Weight Gain in Patients With SchizophreniaCompletedNCT00485823Phase 4
• Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With SchizophreniaCompletedNCT00485810Phase 1/2
• Managing Acute Schizophrenia, a Comparison Between Two Atypical AntipsychoticsCompletedNCT00485498Phase 4
• Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and PsychosisCompletedNCT00484302Not applicable
• A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat SchizophreniaCompletedNCT00483964Phase 2
• MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)CompletedNCT00482430Phase 2
• Functional Neuroimaging Effects of Cognitive Remediation TrainingCompletedNCT00481156Phase 3
• A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and DepressionCompletedNCT00481026Not applicable
• Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus RisperidoneStatus unknownNCT00480844Phase 4
• Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective DisorderCompletedNCT00480571Phase 2
• Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usualCompletedNCT00472862Phase 3
• Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in SchizophreniaStatus unknownNCT00469664Phase 4
• The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole TrialStatus unknownNCT00468533Phase 4
• Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset PsychosisStatus unknownNCT00465920Phase 2
• Donepezil Double Blind Trial for ECT Memory DisfunctionStatus unknownNCT00465283Phase 4
• Galantamine for Cognitive Deficits in SchizophreniaCompletedNCT00463879Phase 2/3
• Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With SchizophreniaCompletedNCT00463372Phase 1
• An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaCompletedNCT00460512Phase 3
• RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical PracticeCompletedNCT00458367

← Schizophrenia overview